Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cells Int ; 2015: 362562, 2015.
Article in English | MEDLINE | ID: mdl-26089913

ABSTRACT

Urine represents an unlimited source of patient-specific kidney cells that can be harvested noninvasively. Urine derived podocytes and proximal tubule cells have been used to study disease mechanisms and to screen for novel drug therapies in a variety of human kidney disorders. The urinary kidney stem/progenitor cells and extracellular vesicles, instead, might be promising for therapeutic treatments of kidney injury. The greatest advantages of urine as a source of viable cells are the easy collection and less complicated ethical issues. However, extensive characterization and in vivo studies still have to be performed before the clinical use of urine-derived kidney progenitors.

2.
Stem Cells Transl Med ; 4(4): 389-400, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25722427

ABSTRACT

The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.


Subject(s)
Cell- and Tissue-Based Therapy/methods , Pluripotent Stem Cells/transplantation , Stem Cell Transplantation , Stem Cells/cytology , Cell- and Tissue-Based Therapy/adverse effects , Humans , Transplantation, Autologous
3.
PLoS One ; 7(4): e35901, 2012.
Article in English | MEDLINE | ID: mdl-22558262

ABSTRACT

Several different interventions improve depressed mood, including medication and environmental factors such as regular physical exercise. The molecular pathways underlying these effects are still not fully understood. In this study, we sought to identify shared mechanisms underlying antidepressant interventions. We studied three groups of mice: mice treated with a widely used antidepressant drug--fluoxetine, mice engaged in voluntary exercise, and mice living in an enriched environment. The hippocampi of treated mice were investigated at the molecular and cellular levels. Mice treated with fluoxetine and mice who exercised daily showed, not only similar antidepressant behavior, but also similar changes in gene expression and hippocampal neurons. These changes were not observed in mice with environmental enrichment. An increase in neurogenesis and dendritic spine density was observed following four weeks of fluoxetine treatment and voluntary exercise. A weighted gene co-expression network analysis revealed four different modules of co-expressed genes that were correlated with the antidepressant effect. This network analysis enabled us to identify genes involved in the molecular pathways underlying the effects of fluoxetine and exercise. The existence of both neuronal and gene expression changes common to antidepressant drug and exercise suggests a shared mechanism underlying their effect. Further studies of these findings may be used to uncover the molecular mechanisms of depression, and to identify new avenues of therapy.


Subject(s)
Antidepressive Agents/pharmacology , Depression/therapy , Exercise Therapy , Fluoxetine/pharmacology , Hippocampus/drug effects , Animals , Depression/genetics , Depression/metabolism , Depression/physiopathology , Gene Expression/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Humans , Male , Metabolic Networks and Pathways , Mice , Mice, Inbred BALB C , Neurogenesis/drug effects , Neurons/drug effects , Neurons/pathology , Physical Conditioning, Animal
SELECTION OF CITATIONS
SEARCH DETAIL
...